Drug Trial Radar · NCT07741331
Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disorder
Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
326
Planned (sponsor's estimate)
Start
Jul 2026
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial includes a short-term study and a long-term study. The short-term study is a multicenter, randomized, double-Blind, double-Dummy, Parallel-Controlled study with a 6-week duration. The long-term study is a withdrawal follow-up study; participants meeting relapse criteria may receive one cycle of KH607 Tablets treatment.
Conditions
- Major Depressive Disorder (MDD)
Interventions
KH607 tabletsDrug
oral 20mg, once daily for 21 days.
Vortioxetine Hydrobromide TabletsDrug
oral 10mg, once daily for 42 days.
Part B: KH607Drug
oral 20mg, once daily for 21 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- short-term study: Change From Baseline in the Montgomery and Åsberg Depression Rating Scale (MADRS) Total ScoreTime frame: Baseline to Day 22
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.